ES2438779T3 - Péptidos administrados oralmente para mejorar aterosclerosis - Google Patents

Péptidos administrados oralmente para mejorar aterosclerosis Download PDF

Info

Publication number
ES2438779T3
ES2438779T3 ES10002402.5T ES10002402T ES2438779T3 ES 2438779 T3 ES2438779 T3 ES 2438779T3 ES 10002402 T ES10002402 T ES 10002402T ES 2438779 T3 ES2438779 T3 ES 2438779T3
Authority
ES
Spain
Prior art keywords
peptide
peptides
group
ldl
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10002402.5T
Other languages
English (en)
Spanish (es)
Inventor
Alan M. Fogelman
Gattadahalli M. Anantharamaiah
Mohammad Navab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
University of California Berkeley
University of California San Diego UCSD
Original Assignee
UAB Research Foundation
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, University of California Berkeley, University of California San Diego UCSD filed Critical UAB Research Foundation
Application granted granted Critical
Publication of ES2438779T3 publication Critical patent/ES2438779T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
ES10002402.5T 2000-08-24 2001-08-23 Péptidos administrados oralmente para mejorar aterosclerosis Expired - Lifetime ES2438779T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645454 1991-01-24
US09/645,454 US6664230B1 (en) 2000-08-24 2000-08-24 Orally administered peptides to ameliorate atherosclerosis

Publications (1)

Publication Number Publication Date
ES2438779T3 true ES2438779T3 (es) 2014-01-20

Family

ID=24589089

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10002402.5T Expired - Lifetime ES2438779T3 (es) 2000-08-24 2001-08-23 Péptidos administrados oralmente para mejorar aterosclerosis
ES01966198T Expired - Lifetime ES2342258T3 (es) 2000-08-24 2001-08-23 Peptidos administrados oralmente para mejorar la aterosclerosis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01966198T Expired - Lifetime ES2342258T3 (es) 2000-08-24 2001-08-23 Peptidos administrados oralmente para mejorar la aterosclerosis.

Country Status (15)

Country Link
US (2) US6664230B1 (https=)
EP (3) EP1864675B1 (https=)
JP (6) JP3822167B2 (https=)
CN (6) CN1943781B (https=)
AT (2) ATE464060T1 (https=)
AU (4) AU2001286732B2 (https=)
CA (3) CA2639651C (https=)
CY (1) CY1110204T1 (https=)
DE (2) DE60144543D1 (https=)
DK (1) DK1318828T3 (https=)
EA (2) EA006488B1 (https=)
ES (2) ES2438779T3 (https=)
IL (3) IL154545A0 (https=)
PT (1) PT1318828E (https=)
WO (1) WO2002015923A1 (https=)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) * 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
DE10222234A1 (de) * 2002-05-16 2003-11-27 Roche Diagnostics Gmbh Kontroll- und Kalibrationsmaterial für Blutgerinnungstests
EP1558275A4 (en) * 2002-10-30 2009-06-24 Us Health TARGETING OF B1 (CLA-1) BUTARY RECEPTOR FOR THE TREATMENT OF INFECTION, SEPSIS AND INFLAMMATION
CA2514303C (en) * 2002-11-13 2012-09-18 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
US20050159362A1 (en) * 2003-04-22 2005-07-21 Sircar Jagadish C. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
TW200503747A (en) * 2003-04-22 2005-02-01 Avanir Pharmaceuticals Peptide mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
FI20060154A7 (fi) * 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
ES2381551T3 (es) 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Marcadores de riesgo para enfermedad cardiovascular
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
ATE463254T1 (de) * 2004-04-15 2010-04-15 Athera Biotechnologies Ab Antikörper gegen phosphorylcholinkonjugate
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200603794A (en) * 2004-06-09 2006-02-01 Avanir Pharmaceuticals Small molecules for treatment of hypercholesterolemia and related diseases
US20060009487A1 (en) * 2004-06-09 2006-01-12 Sircar Jagadish C Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
EP1753782A1 (en) * 2004-06-09 2007-02-21 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
KR101185609B1 (ko) * 2004-07-16 2012-09-24 트러스티즈 오브 터프츠 칼리지 아포리포단백질 ａ１ 미메틱 및 이의 용도
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
EP1789035A2 (en) * 2004-08-11 2007-05-30 The Regents of the University of California-San Francisco Orally administered small peptides synergize statin activity
AU2005287004B2 (en) * 2004-09-16 2011-03-17 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GR1005428B (el) * 2005-05-27 2007-02-01 Χαραλαμπος Αλεξοπουλος Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
GB0513096D0 (en) * 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
CA2672131C (en) * 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux
US20080268038A1 (en) * 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
CA2692698A1 (en) * 2007-07-09 2009-01-15 Novartis Ag Preserving secondary peptide structure
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
DK2193142T3 (da) * 2007-08-30 2015-04-20 Curedm Group Holdings Llc Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
CN105903029A (zh) * 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
EP2324048A2 (en) * 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
JP5719783B2 (ja) 2009-02-16 2015-05-20 セレニス セラピューティクス ホールディング エスアー アポリポタンパクａ−ｉ模倣物
US20120270771A1 (en) * 2009-09-30 2012-10-25 Snu R&Db Foundation Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
NO2385374T3 (https=) 2010-05-05 2014-06-07
CN108445241B (zh) * 2010-06-20 2021-11-02 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
WO2012108990A2 (en) * 2011-02-07 2012-08-16 Indiana University Research And Technology Corporation Peptide-phospholipid conjugates
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
ES2859559T3 (es) * 2012-11-06 2021-10-04 Les Hopitaux Univ De Geneve Péptidos miméticos
US20160002315A1 (en) 2013-03-14 2016-01-07 Uab Research Foundation Apolipoprotein mimetics and uses thereof
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP2018528257A (ja) 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
CN105061579B (zh) * 2015-08-18 2018-08-28 北京大学人民医院 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
WO2018063796A1 (en) 2016-09-28 2018-04-05 The Regents Of The University Of California Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
RU2760498C1 (ru) * 2021-02-09 2021-11-25 Вахтанг Владимирович Гобеджишвили Способ прогнозирования развития избыточного рубцеобразования у больных после проктологической операции
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
US20250066452A1 (en) * 2022-03-03 2025-02-27 University Of Maryland, Baltimore Synthetic amphipathic helical peptides and treatment methods using synthetic amphipathic helical peptides
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025147594A1 (en) * 2024-01-04 2025-07-10 University Of Florida Research Foundation, Incorporated Peptides and method of use in preparing nanodiscs

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
JPH07507554A (ja) 1992-06-12 1995-08-24 エヌ・ブイ・イノゲネテイクス・エス・エイ 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
AU672028B2 (en) 1992-08-14 1996-09-19 Shino-Test Corporation Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
DE69435171D1 (de) * 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
BR9610390A (pt) 1995-09-09 1999-07-06 Hoffmann La Roche O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
CN1109047C (zh) 1996-03-29 2003-05-21 D·博菲利 作为胆固醇和其它脂类摄取抑制剂的两亲分子
US6200955B1 (en) * 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
IN185761B (https=) 1997-05-13 2001-04-28 Council Scient Ind Res
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
WO1999047566A1 (en) 1998-03-17 1999-09-23 The Uab Research Foundation Synthetic peptides that enhance ldl uptake
EP1100818B1 (en) * 1998-07-30 2013-01-02 Whitehead Institute For Biomedical Research Inhibitors of hiv membrane fusion
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
US6933279B2 (en) 2005-08-23
CN1739787A (zh) 2006-03-01
EA200501744A1 (ru) 2006-06-30
EP1318828A4 (en) 2005-04-27
IL154545A (en) 2011-10-31
CA2718348A1 (en) 2002-02-28
DE60141842D1 (de) 2010-05-27
ATE506958T1 (de) 2011-05-15
IL206114A (en) 2014-05-28
AU2006200035A1 (en) 2006-02-02
EP1864675A1 (en) 2007-12-12
EA009528B1 (ru) 2008-02-28
JP2006056899A (ja) 2006-03-02
HK1055400A1 (en) 2004-01-09
AU2009202705B2 (en) 2013-01-10
JP4364222B2 (ja) 2009-11-11
EP1318828A1 (en) 2003-06-18
AU2009202705A1 (en) 2009-07-23
EP2198877A2 (en) 2010-06-23
ATE464060T1 (de) 2010-04-15
HK1110011A1 (en) 2008-07-04
IL154545A0 (en) 2003-09-17
PT1318828E (pt) 2010-06-11
EP2198877A3 (en) 2010-12-01
CN1224419C (zh) 2005-10-26
CN1943781A (zh) 2007-04-11
CN100579984C (zh) 2010-01-13
EP2198877B1 (en) 2013-10-16
CN1931358A (zh) 2007-03-21
CN1469754A (zh) 2004-01-21
JP2004506693A (ja) 2004-03-04
EP1864675B1 (en) 2011-04-27
JP2007277250A (ja) 2007-10-25
DK1318828T3 (da) 2010-08-09
CA2718348C (en) 2012-07-17
AU2006200035B2 (en) 2007-09-13
WO2002015923A1 (en) 2002-02-28
US6664230B1 (en) 2003-12-16
AU2001286732B2 (en) 2005-10-06
CN1931359B (zh) 2014-10-15
JP3822167B2 (ja) 2006-09-13
CN1931359A (zh) 2007-03-21
CA2639651C (en) 2011-02-08
JP2006312650A (ja) 2006-11-16
EA200300289A1 (ru) 2003-08-28
JP2008150358A (ja) 2008-07-03
JP4205713B2 (ja) 2009-01-07
JP2010280718A (ja) 2010-12-16
CN1943781B (zh) 2011-01-12
CA2639651A1 (en) 2002-02-28
CA2420222A1 (en) 2002-02-28
EP1318828B1 (en) 2010-04-14
ES2342258T3 (es) 2010-07-05
US20030045460A1 (en) 2003-03-06
CY1110204T1 (el) 2015-01-14
AU2009202705C1 (en) 2013-10-17
AU8673201A (en) 2002-03-04
EA006488B1 (ru) 2005-12-29
CN1911439A (zh) 2007-02-14
DE60144543D1 (de) 2011-06-09
JP5241790B2 (ja) 2013-07-17
CA2420222C (en) 2009-03-03

Similar Documents

Publication Publication Date Title
ES2438779T3 (es) Péptidos administrados oralmente para mejorar aterosclerosis
US7144862B2 (en) Orally administered peptides to ameliorate atherosclerosis
CA2480217C (en) G-type peptides to ameliorate atherosclerosis
AU2001286732A1 (en) Orally administered peptides to ameliorate atherosclerosis
AU2006242651B2 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2007237157B2 (en) Peptides that ameliorate atherosclerosis
HK1110011B (en) Orally administered peptides to ameliorate atherosclerosis
HK1055400B (en) Orally administered peptides to ameliorate atherosclerosis
HK1072896B (en) G-type peptides to ameliorate atherosclerosis